At the request of the Council on Pharmacy and Chemistry, Dr. Perrin H. Long prepared a preliminary report2 on the thiazole derivatives of sulfanilamide so that the medical profession might be informed about these new drugs. The report was published in The Journal before sulfathiazole was released for interstate commerce as a new drug under the Food, Drug and Cosmetic Act. This preliminary report was followed by a statement3 in The Journal informing the medical profession that certain brands of sulfathiazole had been accepted as conforming to the rules of the Council on Pharmacy and Chemistry for admission to New and Nonofficial Remedies.In the description of the drug which appears in this Council communication, the toxicity, indications for use and suggested dosage are described. Clinically, the drug has been used primarily in the treatment of pneumococcic pneumonia, infections due to Staphylococcus aureus or Escherichia coli, and
Smith AE. SULFATHIAZOLE-WINTHROP CONTAMINATED WITH PHENOBARBITAL: II. CLINICAL ASPECTS. JAMA. 1941;116(20):2259–2261. doi:10.1001/jama.1941.62820200003008a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: